Saturna Capital CORP Boosts Stake in Bristol-Myers Squibb Co. (BMY)
Saturna Capital CORP boosted its stake in Bristol-Myers Squibb Co. (NYSE:BMY) by 0.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 663,238 shares of the biopharmaceutical company’s stock after buying an additional 1,166 shares during the period. Bristol-Myers Squibb accounts for 1.6% of Saturna Capital CORP’s holdings, making the stock its 18th largest position. Saturna Capital CORP’s holdings in Bristol-Myers Squibb were worth $48,781,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Jolley Asset Management LLC increased its stake in shares of Bristol-Myers Squibb by 4.0% in the second quarter. Jolley Asset Management LLC now owns 2,092 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 80 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Bristol-Myers Squibb during the second quarter valued at about $163,000. Solaris Asset Management LLC increased its stake in shares of Bristol-Myers Squibb by 3.5% in the second quarter. Solaris Asset Management LLC now owns 2,244 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 75 shares in the last quarter. Jackson Grant Investment Advisers Inc. increased its stake in shares of Bristol-Myers Squibb by 0.5% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 2,353 shares of the biopharmaceutical company’s stock valued at $173,000 after buying an additional 12 shares in the last quarter. Finally, Madrona Financial Services LLC bought a new stake in shares of Bristol-Myers Squibb during the second quarter valued at about $200,000. 72.95% of the stock is currently owned by institutional investors and hedge funds.
Bristol-Myers Squibb Co. (NYSE:BMY) traded up 0.87% on Tuesday, hitting $55.56. 9,934,824 shares of the company were exchanged. The firm has a market cap of $92.83 billion, a price-to-earnings ratio of 32.49 and a beta of 0.61. Bristol-Myers Squibb Co. has a one year low of $55.02 and a one year high of $77.12. The stock has a 50 day moving average price of $60.17 and a 200 day moving average price of $67.73.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.03. Bristol-Myers Squibb had a net margin of 16.63% and a return on equity of 24.92%. The company had revenue of $4.90 billion for the quarter, compared to the consensus estimate of $4.60 billion. During the same quarter in the previous year, the firm posted $0.53 EPS. The business’s revenue was up 17.2% compared to the same quarter last year. On average, equities research analysts forecast that Bristol-Myers Squibb Co. will post $2.63 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 1st. Stockholders of record on Friday, October 7th will be issued a dividend of $0.38 per share. The ex-dividend date is Wednesday, October 5th. This represents a $1.52 annualized dividend and a dividend yield of 2.74%. Bristol-Myers Squibb’s payout ratio is 87.36%.
Several brokerages recently issued reports on BMY. Jefferies Group increased their price target on Bristol-Myers Squibb from $77.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, July 14th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $85.00 price target for the company in a report on Wednesday, July 13th. Berenberg Bank reiterated a “buy” rating on shares of Bristol-Myers Squibb in a report on Tuesday, July 12th. Vetr upgraded Bristol-Myers Squibb from a “sell” rating to a “buy” rating and set a $78.73 price target for the company in a report on Monday, July 25th. Finally, SunTrust Banks Inc. downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the company from $86.00 to $68.00 in a report on Friday, August 5th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $69.64.
In related news, Director Lamberto Andreotti sold 23,200 shares of the company’s stock in a transaction dated Friday, July 8th. The shares were sold at an average price of $74.45, for a total value of $1,727,240.00. Following the sale, the director now owns 380,099 shares of the company’s stock, valued at $28,298,370.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.24% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.